Download summaryDownload full report

Capitol Counsel, on behalf of the Part B Access for Seniors and Providers Coalition, commissioned Milliman to quantify the potential impact of the Inflation Reduction Act (IRA) and its changes to Medicare Part B reimbursement on physician reimbursement and patient access to care. We analyzed the financial impact resulting from the Medicare Drug Price Negotiation Program (MDPNP) enacted by the IRA, as well as the impact of an alternative scenario in which the Protecting Patient Access to Cancer and Complex Therapies Act (PACTA) is passed. We modeled a 10-year window, beginning in 2028, which is the initial year Part B drugs are eligible for the MDPNP. In the report, we cover the following:

• Background on provider reimbursement, Medicare benefit structure, sequestration, and stakeholder cash flows
• Analysis of impact on Part B stakeholders: providers, patients, government, plans, and pharmaceutical manufacturers
• Discussion of provider behavior and patient access, provider consolidation, and other considerations

This report was commissioned by Capitol Counsel, on behalf of the Part B Access for Seniors and Providers Coalition.